Continuous glucose monitoring for non-insulin type 2 diabetes in primary care
Many adults with type 2 diabetes receive treatment in primary care without needing insulin therapy. While continuous glucose monitoring (CGM) is established as a core tool for people with type 1 diabetes and those using insulin, its role in managing non-insulin-treated type 2 diabetes has remained uncertain. Primary care clinicians and informaticians frequently weigh whether wearable sensors offer clinical value beyond standard routine care for patients managing their condition through lifestyle changes or non-insulin medications.
A randomised trial in primary care practice
To evaluate this approach, a 26-week multicentre randomised controlled trial was conducted across 22 primary care practices in the United States. The trial enrolled 283 adults aged 21 to 84 years with type 2 diabetes who were not receiving insulin. Participants were randomly assigned to either CGM (145 participants) or routine care (138 participants).
The primary outcome was the glycated haemoglobin level measured at 26 weeks. Secondary outcomes captured by continuous monitoring were evaluated hierarchically to control the overall type I error rate. The study received funding support from Dexcom.
Key findings on glycated haemoglobin and time in range
At baseline, mean glycated haemoglobin levels were 8.8% (±1.3%) in the CGM group and 8.7% (±1.2%) in the routine-care group. By week 26, mean glycated haemoglobin dropped to 7.2% (±1.1%) in the CGM group compared to 8.0% (±1.4%) in the routine-care group. This produced an adjusted mean difference of -0.9 percentage points (95% confidence interval [CI], -1.1 to -0.6; P<0.001) in favour of continuous monitoring.
Secondary sensor-derived outcomes showed additional differences between the two study arms:
- Participants using CGM spent an average of 21 percentage points more time in the target range of 70 to 180 mg per decilitre than those receiving routine care (95% CI, 16 to 26; P<0.001).
- The between-group difference in time spent below 54 mg per decilitre was -0.17 percentage points (95% CI, -0.27 to -0.11; P<0.001 for non-inferiority).
- The difference in time spent below 70 mg per decilitre was -0.20 percentage points (95% CI, -0.43 to -0.09; P<0.001 for non-inferiority; P = 0.004 for superiority).
- No severe hypoglycaemia events occurred in either group during the study period.
What the findings mean for clinical practice and health systems
For primary care providers, these results demonstrate that continuous glucose monitoring can assist in reducing glycated haemoglobin and hyperglycemia in non-insulin-treated type 2 diabetes without increasing low blood sugar events. From a health informatics standpoint, integrating sensor readings into primary care workflows offers continuous data that can guide therapy choices and lifestyle adjustments.
However, implementing continuous glucose monitoring requires sensors, reading devices, and software infrastructure. In low-resource settings, the financial cost of hardware and supply chains may present a barrier compared to routine care protocols. Healthcare organisations must consider whether a 0.9 percentage point drop in glycated haemoglobin over six months justifies the direct device costs and data management demands.
Study design limitations and remaining questions
As a 26-week randomised controlled trial, this study provides clear evidence of medium-term efficacy, but several limitations remain:
- The 26-week duration leaves open questions about whether these glucose reductions persist over longer periods or whether patient engagement with wearable sensors declines over time.
- The trial took place exclusively in US primary care settings, which may limit direct application to health systems with different funding mechanisms or clinical workflows.
- The abstract does not specify what medication changes or behavioral interventions occurred alongside sensor use in either group.
- The trial was funded by a commercial sensor manufacturer, which warrants standard critical evaluation when interpreting the outcomes.
Reference
Oser TK, Martens T, Ruedy KJ, Bergford S, Calhoun P, Chang KL, et al.. Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2608571. PMID: 42878622.
This research digest summarises a recently published article. It was drafted with AI assistance from the article's abstract and reviewed by the author before publication.

Comments